Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Jun 29, 2026, 10:31 ET

      Share this article

      Share this article


      The anticipated increase in the nephrotic syndrome market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition. Additionally, the expected launch of novel emerging therapies such as Inaxaplin (VX-147) (Vertex Pharmaceuticals), Apecotrep (BI 764198) (Boehringer Ingelheim), GAZYVA/GAZYVARO (obinutuzumab) (Roche), and others will further propel the market growth.

      LAS VEGAS, June 29, 2026 /PRNewswire/ -- Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

      Nephrotic Syndrome Market Summary

      • The total market size of nephrotic syndrome in the 7MM in 2025 was approximately USD 400 million.
      • The United States accounted for the largest nephrotic syndrome treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
      • The total diagnosed prevalent cases of nephrotic syndrome in the 7MM were ~800,000 in 2025. These cases are expected to increase during the forecast period (2026–2036).
      • Leading nephrotic syndrome companies, such as Vertex Pharmaceuticals, Boehringer Ingelheim, Roche, Kezar Life Sciences, Vera Therapeutics, Walden Biosciences, and others, are developing new nephrotic syndrome treatment drugs that can be available in the nephrotic syndrome market in the coming years. 
      • The promising nephrotic syndrome therapies in clinical trials include Inaxaplin (VX-147), Apecotrep (BI 764198), GAZYVA/GAZYVARO (obinutuzumab), Zetomipzomib (KZR-616), Atacicept, WAL0921, and others.

      Discover the nephrotic syndrome drug pipeline analysis report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-market

      Key Factors Driving the Growth of the Nephrotic Syndrome Market 

      • Rising Prevalence of Kidney Disorders: The increasing incidence of chronic kidney diseases, diabetes, and autoimmune conditions is contributing to a larger patient pool requiring nephrotic syndrome treatment.
      • Advancements in Targeted Therapies: The development of novel biologics, immunosuppressants, and precision medicines is improving treatment outcomes and expanding therapeutic options.
      • Advancements in Targeted Therapies: The development of novel biologics, immunosuppressants, and precision medicines is improving treatment outcomes and expanding therapeutic options.
      • Robust Clinical Pipeline: A strong pipeline of emerging therapies, including Inaxaplin (VX-147) (Vertex Pharmaceuticals), Apecotrep (BI 764198) (Boehringer Ingelheim), GAZYVA/GAZYVARO (obinutuzumab) (Roche), Zetomipzomib (KZR-616) (Kezar Life Sciences), Atacicept (Vera Therapeutics), WAL0921 (Walden Biosciences), and others, is expected to drive market expansion over the coming years.

      Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that the ongoing research on new targets for treatment, such as complement inhibitors and podocyte-specific therapies, offers the potential for more effective and targeted interventions. 

      Nephrotic Syndrome Market Analysis

      • Treatment of nephrotic syndrome is primarily aimed at treating the underlying disease, alleviating symptoms, reducing protein loss, and preventing long-term complications. Management typically involves a combination of pharmacological interventions, dietary adjustments, and supportive care strategies tailored to the patient's clinical presentation and treatment response.
      • Pharmacotherapy remains the cornerstone of nephrotic syndrome management. Corticosteroids, particularly prednisone, are widely used as first-line therapy in steroid-responsive conditions such as minimal change disease and certain cases of FSGS.
      • These agents help suppress inflammation and modulate immune activity, thereby reducing proteinuria and improving renal outcomes. For patients who are steroid-resistant, steroid-dependent, or experiencing recurrent disease, immunosuppressive therapies, including calcineurin inhibitors such as cyclosporine and tacrolimus, as well as alkylating agents like cyclophosphamide, may be utilized to limit immune-mediated glomerular injury.
      • Edema, a hallmark feature of nephrotic syndrome, is commonly managed with diuretics such as furosemide, which promote the elimination of excess fluid. Careful monitoring is required to prevent complications such as dehydration and electrolyte disturbances. 
      • In addition, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), including enalapril and losartan, are frequently prescribed to reduce proteinuria, preserve kidney function, and control hypertension, which often accompanies the disease.
      • Lipid-lowering agents, particularly statins, are also commonly incorporated into treatment regimens to address nephrotic syndrome-associated hyperlipidemia and mitigate the increased risk of cardiovascular complications.
      • Nutritional management serves as an important adjunct to medical therapy. Restricting sodium intake can help minimize fluid retention and edema, while carefully monitored protein intake may aid in reducing proteinuria without compromising nutritional status. Dietary counseling is often recommended to ensure individualized nutritional support.
      • The nephrotic syndrome therapeutic landscape is also evolving, with several investigational therapies under clinical development. Notable pipeline candidates include inaxaplin from Vertex Pharmaceuticals, GAZYVA/GAZYVARO (obinutuzumab) from Roche, and apecotrep (BI 764198) from Boehringer Ingelheim, among others, which are being evaluated for their potential to address unmet needs and improve clinical outcomes in patients with nephrotic syndrome.

      Nephrotic Syndrome Competitive Landscape

      Some of th nephrotic syndrome drugs under development include Inaxaplin (VX-147) (Vertex Pharmaceuticals), Apecotrep (BI 764198) (Boehringer Ingelheim), GAZYVA/GAZYVARO (obinutuzumab) (Roche), Zetomipzomib (KZR-616) (Kezar Life Sciences), Atacicept (Vera Therapeutics), WAL0921 (Walden Biosciences), and others.

      Vertex Pharmaceuticals' Inaxaplin (previously VX-147) is an orally administered small-molecule inhibitor of apolipoprotein L1 (APOL1) being developed by Vertex Pharmaceuticals for the treatment of APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney disorders. It is the first investigational therapy specifically designed to address the underlying genetic driver of APOL1-mediated kidney disease (AMKD).

      Boehringer Ingelheim's Apecotrep (BI 764198) is an oral transient receptor potential cation channel subfamily C member 6 (TRPC6) inhibitor under development by Boehringer Ingelheim for patients with FSGS. The candidate has received orphan drug designation from both the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare, recognizing its potential in treating this rare kidney disorder.

      Roche's GAZYVA/GAZYVARO (obinutuzumab) is a humanized anti-CD20 monoclonal antibody engineered with a Type II CD20-binding domain that promotes direct B-cell elimination, along with a glycoengineered Fc region that enhances binding affinity and antibody-dependent cellular cytotoxicity (ADCC). By targeting CD20-expressing B cells, the therapy exerts potent immunomodulatory effects and is also approved for the treatment of Lupus Nephritis.

      The anticipated launch of these emerging therapies are poised to transform the nephrotic syndrome market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the nephrotic syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about the nephrotic syndrome management @ Nephrotic Syndrome Treatment Options

      Recent Developments in the Nephrotic Syndrome Market

      • In February 2026, Roche reported positive Phase III results from the MAJESTY trial, the first global Phase III study evaluating GAZYVA (obinutuzumab) in patients with primary membranous nephropathy. 
      • In January 2026, Boehringer Ingelheim reported results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor, in patients with FSGS. The study demonstrated that the 20 mg dose of apecotrep reduced proteinuria by 40% compared with placebo.

      What is Nephrotic Syndrome?

      Nephrotic syndrome is a kidney disorder characterized by excessive loss of protein in the urine due to damage to the glomeruli, the tiny filtering units of the kidneys. This condition is typically marked by a combination of proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Nephrotic syndrome can result from various underlying causes, including primary kidney diseases such as minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy, as well as systemic conditions like diabetes, lupus, and infections. If left untreated, it can lead to complications such as increased susceptibility to infections, blood clots, and progressive kidney dysfunction, making early diagnosis and appropriate management essential.

      Nephrotic Syndrome Epidemiology Segmentation

      The nephrotic syndrome epidemiology section provides insights into the historical and current nephrotic syndrome patient pool and forecasted trends for the leading markets. According to DelveInsight's analysts, there were ~150,000 diagnosed prevalent cases of nephrotic syndrome in Japan in 2025, and this number is expected to change by 2036.

      The nephrotic syndrome treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

      • Diagnosed Prevalent Cases of Nephrotic Syndrome
      • Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome 

      Nephrotic Syndrome Market Report Metrics

      Details

      Study Period

      2022–2036

      Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Nephrotic Syndrome Epidemiology Segmentation

      Diagnosed Prevalent Cases of Nephrotic Syndrome and Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome 

      Nephrotic Syndrome Market Size in 2025

      USD 400 Million

      Key Nephrotic Syndrome Companies

      Vertex Pharmaceuticals, Boehringer Ingelheim, Roche, Kezar Life Sciences, Vera Therapeutics, Walden Biosciences, Aurinia Pharmaceuticals, Otsuka Pharmaceutical, GSK, Johnson & Johnson, Travere Therapeutics, CSL Vifor, Calliditas Therapeutics AB, and others

      Key Nephrotic Syndrome Therapies

      Inaxaplin (VX-147), Apecotrep (BI 764198), GAZYVA/GAZYVARO (obinutuzumab), Zetomipzomib (KZR-616), Atacicept, WAL0921, LUPKYNIS, BENLYSTA, INVOKANA, FILSPARI, TARPEYO, and others

      Scope of the Nephrotic Syndrome Market Report

      • Nephrotic Syndrome Patient Population Forecast
      • Nephrotic Syndrome Therapeutics Market Size
      • Nephrotic Syndrome Pipeline Analysis
      • Nephrotic Syndrome Market Size and Trends
      • Nephrotic Syndrome Market Opportunity
      • Nephrotic Syndrome Market Unmet Needs
      • KOL's Views on Nephrotic Syndrome
      • Nephrotic Syndrome Market Access and Reimbursement

      Download the report to understand more about nephrotic syndrome medications @ Nephrotic Syndrome Immunosuppressive Drug

      Table of Contents

      1

      Nephrotic Syndrome Market Key Insights

      2

      Nephrotic Syndrome Market Report Introduction

      3

      Nephrotic Syndrome Market Overview at a Glance

      3.1

      Market Share (%) Distribution of Nephrotic Syndrome by Therapies in the 7MM in 2025

      3.2

      Market Share (%) Distribution of Nephrotic Syndrome by Therapies in the 7MM in 2036

      4

      Epidemiology and Market Methodology of Nephrotic Syndrome

      5

      Executive Summary of Nephrotic Syndrome

      6

      Key Events

      7

      Nephrotic Syndrome: Disease Background and Overview

      7.1

      Introduction

      7.2

      Etiology

      7.3

      Clinical Manifestation

      7.4

      Complications

      7.5

      Pathophysiology

      7.6

      Diagnosis

      7.7

      Management and Treatment

      7.8

      Guidelines

      8

      Epidemiology and Patient Population

      8.1

      Key Findings

      8.2

      Assumptions and Rationale: The 7MM

      8.2.1

      FSGS

      8.2.2

      IgA Nephropathy

      8.2.3

      Membranous Nephropathy

      8.2.4

      Others

      8.3

      Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the 7MM

      8.4

      The United States

      8.4.1

      Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the US

      8.4.2

      Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the US

      8.5

      EU4 and the UK

      8.6

      Japan

      9

      Patient Journey

      10

      Marketed Nephrotic Syndrome Drugs

      10.1

      Key Competitors

      10.2

      LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceutical

      10.2.1

      Product Description

      10.2.2

      Regulatory Milestones

      10.2.3

      Other Developmental Activities

      10.2.4

      Clinical Trials Information

      10.2.5

      Safety and Efficacy

      10.2.6

      Analyst Views

      10.3

      BENLYSTA (belimumab): GSK

      10.4

      INVOKANA (Canagliflozin): Johnson & Johnson

      10.5

      FILSPARI (sparsentan): Travere Therapeutics/CSL Vifor

      10.6

      TARPEYO (budesonide): Calliditas Therapeutics AB

      List to be continued in the report….

      11

      Emerging Nephrotic Syndrome Therapies

      11.1

      Key Cross Competition

      11.2

      Inaxaplin (VX-147): Vertex Pharmaceuticals

      11.2.1

      Product description

      11.2.2

      Other development activities

      11.2.3

      Clinical trials information

      11.2.4

      Safety and efficacy

      11.2.5

      Analyst Views

      11.3

      GAZYVA/GAZYVARO (obinutuzumab): Hoffman La Roche

      11.4

      Apecotrep (BI 764198): Boehringer Ingelheim

      List to be continued in the report…

      12

      Nephrotic Syndrome: Market Analysis

      12.1

      Key Findings

      12.2

      Key Nephrotic Syndrome Market Forecast Assumptions

      12.3

      Nephrotic Syndrome Market Outlook

      12.4

      Attribute Analysis

      12.5

      Total Market Size of Nephrotic Syndrome in the 7MM

      12.6

      Total Market Size of Nephrotic Syndrome by Therapies in the 7MM

      12.7

      Market Size of Nephrotic Syndrome in the US

      12.7.1

      Total Market Size of Nephrotic Syndrome

      12.7.2

      The Market Size of Nephrotic Syndrome by Therapies

      12.8

      Market Size of Nephrotic Syndrome in EU4 and the UK

      12.9

      Market Size of Nephrotic Syndrome in Japan

      13

      Key Opinion Leaders' Views

      14

      Unmet Needs

      15

      SWOT Analysis

      16

      Nephrotic Syndrome Market Access and Reimbursement

      16.1

      The US

      16.2

      In EU4 and the UK

      16.3

      Japan

      17

      Bibliography

      18

      Acronyms and Abbreviations

      19

      Nephrotic Syndrome Market Report Methodology

      Related Reports

      Nephrotic Syndrome Clinical Trial Analysis 

      Nephrotic Syndrome Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nephrotic syndrome companies, including GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others.

      Focal Segmental Glomerulosclerosis Market

      Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key FSGS companies including Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company, and others.

      Membranous Nephropathy Market

      Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key membranous nephropathy companies including Argenx, Zai Lab Pty Ltd., Shanghai Jiaolian Drug Research and Development Co. Ltd., Shanghai Pharmaceuticals Holding Co. Ltd, Acelyrin, Beijing Mabworks Biotech Co Ltd., Cerium Pharmaceuticals Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Gilead Sciences, Mallinckrodt, Mayo Clinic, Genentech Inc., GlaxoSmithKline, Roche Pharma AG, Apellis Pharmaceuticals Inc., and others.

      IgA Nephropathy Market

      IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IgAN companies including Travere Therapeutics, Novartis, Asahi Kasei, Calliditas Therapeutics, Biogen, AstraZeneca (Alexion Pharmaceuticals), and others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur  
      [email protected]
      +14699457679
      www.delveinsight.com

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.